Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut für Pharmakologie und Präventive Medizin
Investigation of changes in blood pressure after six weeks therapy with a fixed combination of 40 mg olmesartan and 10 mg amlodipine compared to a monotherapy with 32 mg candesartan. Investigation of changes in dipping-profile after a further six weeks of therapy with the fixed combination when time of intake is switched from morning to evening.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
essential hypertension, i. e. systolic OPM \>=140 mmHg at screening and \>=160 mmHg after two weeks wash-out
You may not be if
systolic office bp \> 180 mm Hg at screening visit
* known hypertensive retinopathy GIII or IV
* recent (\< 4 weeks ago) myocardial infarction or indication for coronary or peripheral revascularisation
* type I diabetes or poorly controlled (HbA1c \>= 8) type II diabetes
* chronic heart failure NYHA III or IV
* prior stroke or TIA
* creatinine clearance \< 60 ml/min or condition after kidney transplant
* moderately or severely impaired liver function (ALT or AST or bilirubin more than double normal value)
* women of childbearing potential without highly effective contraception, pregnant or breastfeeding women
* concomitant therapy with lithium
* hemodynamically relevant mitral or aortic valve stenosis (\>= II°) or hypertrophic obstructive cardiomyopathy
* concomitant therapy with strong CYP3A4 inhibitors or inductors
* african patients
* concomitant severe psychiatric condition that might impair proper intake of study medication
* life expectancy \< 6 months
* night shift workers
* known other mandatory indication for treatment with antihypertensive medications
